Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

32.1K
Overview
32.1K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hantavirus seroprevalence and associated factors for exposure in south-central Uganda.

Emerging microbes & infections·2026
Same author

A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge.

Science translational medicine·2025
Same author

Negative Pressure Wound Therapy: A Novel Technique for Treatment of Chylous Fistula After Neck Surgery.

The Annals of otology, rhinology, and laryngology·2025
Same author

Highly pathogenic avian influenza H5N1 clade 2.3.4.4b genotype B3.13 is highly virulent for mice, rapidly causing acute pulmonary and neurologic disease.

Nature communications·2025
Same author

Molecular cloning and host range analysis of three cytomegaloviruses from <i>Mastomys natalensis</i>.

Journal of virology·2025
Same author

Longitudinal seroprevalence of Crimean-Congo hemorrhagic fever virus in Southern Uganda.

Emerging microbes & infections·2025
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.7K

Targeting Ebola virus replication through pharmaceutical intervention.

Frederick Hansen1, Heinz Feldmann1, Michael A Jarvis1,2,3

  • 1Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.

Expert Opinion on Investigational Drugs
|February 17, 2021
PubMed
Summary
This summary is machine-generated.

Developing effective treatments for filoviruses like Ebola virus (EBOV) is crucial. Direct-acting antivirals, especially monoclonal antibodies, show more promise than host-directed drugs for treating EBOV infections.

Keywords:
AntiviralEbola virus (EBOV)Ebola virus disease (EVD)InmazebTMebolavirusesemerging/reemerging infectious diseasehost-directedmonoclonal antibodiesnucleoside analogrepurposing

More Related Videos

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

4.0K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.1K

Related Experiment Videos

Last Updated: Nov 17, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.7K
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

4.0K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.1K

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmaceutical Development

Background:

  • Filoviruses, including Ebola virus (EBOV), pose significant global health threats due to their emergence and reemergence.
  • Historically, there has been a lack of approved pharmaceutical interventions for many emerging zoonotic viruses.
  • Proactive development of cost-effective countermeasures against high-impact emerging viruses is a critical priority.

Purpose of the Study:

  • To review and categorize candidate pharmaceutical interventions for Ebola virus infections.
  • To evaluate the translation of preclinical findings to clinical efficacy for different drug classes.
  • To discuss strategies for improving therapeutic outcomes and addressing accessibility challenges.

Main Methods:

  • Literature search of PubMed and Web of Science databases.
  • Cataloging of candidate antiviral drugs targeting Ebola virus.
  • Analysis of drug efficacy based on in vitro and in vivo data.

Main Results:

  • Many host-directed drugs show in vitro activity but limited in vivo efficacy against EBOV.
  • Direct-acting antivirals, particularly monoclonal antibodies, demonstrate better translation to clinical success.
  • Inmazeb™, an FDA-approved monoclonal antibody, represents a significant advancement but may benefit from combination therapies.

Conclusions:

  • Direct-acting antivirals are more promising for treating Ebola virus disease than repurposed host-directed drugs.
  • Combination therapies targeting different viral mechanisms could enhance treatment effectiveness.
  • Addressing cost and accessibility is essential for global impact, especially in under-resourced regions.